free audio
free audio with http://www.mdnewscast.net

free audio

Medical Newscast

News for 17-Sep-26

Source: MedicineNet Diabetes General
Health Tip: Prepare for Travel With Diabetes

Source: MedicineNet High Blood Pressure General
High Blood Pressure Rates Have Doubled Worldwide Since 1975

Source: MedicineNet Diabetes General
glipizide and metformin (Metaglip has been discontinued in the US)

Source: MedicineNet High Blood Pressure General
Study Finds Worrisome Heart Effects Among Some Football Players

Source: MedicineNet Diabetes General
Health Tip: Creating an Insulin Routine

Source: MedicineNet High Blood Pressure General
Bonus From Your Blood Pressure Med: Fewer Fractures?

Source: MedicineNet High Blood Pressure General
Even Small Rise in Blood Pressure Can Harm Black Patients

Source: MedicineNet High Blood Pressure General
Stressed Childhood Might Raise Risk for High Blood Pressure Later

Source: MedicineNet Diabetes General
Daily Can of Soda Boosts Odds for Prediabetes, Study Finds

Source: MedicineNet Diabetes General
Low Blood Sugar Linked to Death Risk for Hospital Patients

Search the Web
free audio
pro audio
audio visual
news radio
radio button
satellite radio
am radio
radio stations in
pci multimedia audio
cbc radio

The Best free audio website

All the free audio information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best free audio site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
free audio.

free audio

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

If you want specific information, such as information about free audio Web directories are the way to go, because they search all the contents of a website. Indexes use software programs called spiders and robots that scour the Internet, analyzing millions of web pages and newsgroup postings and indexing all of the words, including free audio.

Indexes like AltaVista and Google find individual pages of a free audio website that match your search criteria, even if the site itself has nothing to do with what you are looking for. You can often find unexpected gems of information this way, but be prepared to wade through a lot of irrelevant information too. Our free audio information is apposite.

Search results may be ranked in order of relevancy eg the number of times your free audio search term appears in a document or how closely the free audio document appears to match a concept you have entered. This is a much more thorough way to locate what you want. Alternatively you can go with our free audio recommendations and save a lot of time.

free audio

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

Welcome to free audio Central, we are so excited to bring to you this new site that we have created. If you've been searching the net looking for as much as you can about free audio then look no more, that's right, you're here!

I have been devoted to find as much as I can about free audio on the net for quite some time now and believe I've finally done it. Directly below this paragraph are the links that I have come up with that relate to free audio. I believe these links are the some of the best and most informative sites around.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
MD Newscast | Medical Meetings | Medical Newscast | MD Newscast | Affordable Used Cars

Medical Meetings On The Net   Doctors On-the-Net   Medical Presentations